SPR965, a Dual PI3K/mTOR Inhibitor, as a Targeted Therapy in Ovarian Cancer

SPR965, a Dual PI3K/mTOR Inhibitor, as a Targeted Therapy in Ovarian Cancer

SPR965 is an inhibitor of PI3K and mTOR C1/C2 and has demonstrated anti-tumorigenic activity in a variety of solid tumors. We sought to determine the effects of SPR965 on cell proliferation and tumor growth in human serous ovarian cancer cell lines and a transgenic mouse model of high grade serous o...

Full description

Bibliographic Details
Main Authors: Arthur-Quan Tran, Stephanie A. Sullivan, Leo Li-Ying Chan, Yajie Yin, Wenchuan Sun, Ziwei Fang, Sundeep Dugar, Chunxiao Zhou, Victoria Bae-Jump
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-02-01
Series:Frontiers in Oncology
Subjects:
SPR965
cell proliferation
invasion
cell stress
ovarian cancer
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2020.624498/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2020.624498/full

Similar Items